Fish Oil Concentration & Refinement Market Size & Share 2026-2035

Fish Oil Concentration and Refinement Market Size

The global fish oil concentration and refinement market generated USD 2.6 billion in 2025 and is projected to reach USD 5 billion by 2035, expanding at approximately 6.8% CAGR during 2026–2035.

The market captures the value-added processing stage between crude marine oil and formulated end use: processors concentrate EPA and DHA, remove unwanted fractions and contaminants, and provide standardized ingredients in formats suitable for dietary supplements, prescription products, clinical nutrition, food fortification, infant formula, aquaculture, and pet nutrition. Its economics are therefore shaped by both revenue and volume, but the commercial premium is attached to verified composition, traceability, and format rather than to crude-oil tonnage alone.

Broader omega-3 ingredient demand supports that premium. Global EPA and DHA ingredient volume reached about 136,000 metric tons in 2025, up 2.6% year over year, while market value was about USD 2.53 billion after prices eased from the supply shock of 2023–2024 ^{[1]GOED, GOED Publishes 2026 Ingredient Market Report, June 2025, goedomega3.com}. Consumer-facing EPA and DHA finished products reached USD 55.4 billion in 2025. Concentration and refinement suppliers address a narrower, higher-specification portion of that opportunity, where customers purchase reliable EPA/DHA content, oxidation control, documentation, and a format compatible with their formulation or regulatory file.

Supply availability remains the market's binding condition. Peru typically supplies roughly 25–33% of global fish oil through its north-central anchoveta fishery ^{[2]FAO GLOBEFISH, Fishmeal and Fish Oil Species Analysis, 2024, fao.org}. The 2023 El Niño disrupted that base: catches across the two Peruvian seasons fell to around 1.885 million tonnes, global fish oil output declined about 21%, and inventories were drawn down. Production recovered partly in 2024, with global output up approximately 12% as Peruvian north-centre quotas were substantially fulfilled, although declines in Chile and Northern Europe limited the offset. Output rose about 5% in the first ten months of 2025, but juvenile incidence and environmental stress again constrained Peru's first season. This pattern makes conversion yield, procurement discipline, and feedstock optionality central to growth rather than merely operational considerations.

Scale alone will not resolve that tension. High-purity output requires validated processing, analytical control, and documentation that are difficult to recreate after a supply disruption. KD Pharma's October 2024 acquisition of dsm-firmenich's marine-lipids business combined large-volume supply infrastructure with high-concentration capability. The strategic consequence is a market in which integrated platforms can direct scarce material toward the most demanding applications, whereas single-format suppliers remain more exposed to price-sensitive supplement demand.

The market covers global fish oil concentration and refinement by concentration and refinement technology, output product form, application, and source species. The analysis spans North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, with material country-level distinctions. Historic analysis covers 2022–2025, with 2025 as the base year; the forecast period is 2026–2035. Company coverage comprises BASF SE, dsm-firmenich, Epax Norway AS, KD Pharma Group SA, Golden Omega, GC Rieber VivoMega AS, Polaris, OLVEA Fish Oils, Lysi hf, Croda International, KinOmega Biopharm, Sinomega Biotech Engineering Co., Ltd., Wiley Companies/AlaskOmega, Aker BioMarine Antarctic AS, and Nissui Pharmaceutical Co., Ltd.

Key Drivers

Regulated clinical and infant-nutrition demand

Demand from pharmaceutical and clinical nutrition uses is more resilient than demand based solely on supplement promotions because it depends on prescribed formulations, batch specifications, and documented quality systems. This application generated USD 423.1 million in 2025 and is forecast to grow at approximately 7.8% CAGR to USD 895.1 million by 2035. For processors, that channel shifts competition away from lowest-cost oil toward API-grade inputs, reproducible EPA/DHA concentration, and evidence packages accepted by drug or nutrition customers.

Infant formula regulation creates a second demand floor. Commission Delegated Regulation (EU) 2016/127 requires DHA in infant formula placed on the EU market, effective from February 2020 ^{[3]EUR-Lex, Commission Delegated Regulation (EU) 2016/127, consolidated October 2024, eur-lex.europa.eu}. China's GB 10765-2021 revision triggered extensive reformulation; 592 formulas from 97 companies were approved under the updated framework in 2023. These rules do not automatically favor every fish-oil ingredient, but they favor suppliers able to deliver certified DHA-bearing material consistently and support customers through qualification. The infant and maternal nutrition segment is forecast to expand from USD 231.3 million in 2025 at approximately 6.9% CAGR.

Premiumization through rTG and phospholipid formats

Format upgrading increases processing value per unit of marine oil. rTG requires an additional enzymatic re-esterification stage after concentration, and it is positioned around absorption performance rather than EPA/DHA content alone. In a 16-week randomized trial, products with more than 95% triglyceride re-esterification produced higher blood EPA and DHA measures than less fully re-esterified preparations. That evidence supports, but does not guarantee, price realization across retail markets. It does explain why rTG is forecast to grow about 8.3% annually, faster than standard EE, and why enzymatic processing is expected to grow about 9.2%.

Higher utilization of constrained feedstock

Seasonal scarcity encourages technologies that raise concentration, recover specific fractions, and enable differentiated end formats. Supercritical CO₂ processing can fractionate omega-3 fatty acids under relatively low-temperature conditions, making it relevant where thermal exposure and solvent controls matter. The practical driver is not technology adoption for its own sake: processors can deploy it alongside distillation to target higher-concentration products and optimize a feedstock base whose supply can move abruptly with quotas and ocean conditions.

Key Restraints

Peru-centered feedstock and climate risk

A refined-oil processor cannot fully diversify away the commodity base when a large share of global crude fish oil originates in one fishery. Peru's 25–33% contribution to global supply means quota decisions, juvenile abundance, and ocean conditions can change raw-material availability faster than downstream demand can adjust ^{[4]IFFO, IFFO's Estimates for 2024's Fishmeal and Fish Oil Production, 2024, iffo.com}. The 2023 output decline illustrated the consequence: inventory drawdowns and elevated input costs reach customers through longer lead times, smaller allocations, or margin pressure. Chile, Iceland, and Norway add supply diversity, but their scale does not make them a complete substitute for a material Peruvian shortfall.

Capital and qualification barriers in high-purity processing

Entry into pharmaceutical-grade or advanced rTG supply requires more than a distillation unit. Equipment must be integrated with quality systems, analytical testing, and documentation that customers can use in regulated supply chains. GC Rieber VivoMega completed a USD 75 million expansion in 2024, while Epax announced a USD 10 million Aalesund investment in 2025. Those investments signal both an opportunity and a constraint: capacity can be added, but the time and capital required protect established operators and slow the response to demand spikes.

The restraint is equally structural: a processor can improve conversion efficiency but cannot manufacture a Peruvian fishing season. The firms best positioned for the forecast period will pair qualification depth with procurement resilience, including access to multiple species, by-product streams, and formats that can absorb differing feedstock profiles. High capex is therefore double-sided. It limits industry-wide capacity responsiveness, but it also reinforces incumbents' ability to retain premium customers when supply tightens.

Fish Oil Concentration and Refinement Market Segment Analysis

By concentration and refinement technology

Molecular distillation is the market's revenue anchor, accounting for USD 1,306.7 million in 2025 and projected to reach USD 2,337.3 million by 2035. Its position reflects broad industrial applicability: it can support repeatable concentration while serving as the base step for subsequent processing. Wiped-film distillation, valued at USD 482.4 million in 2025, is forecast to outgrow short-path distillation because it fits higher-throughput and continuous configurations. BASF's PronovaPure portfolio demonstrates the commercial relevance of this platform, with EPA and DHA concentrate offerings specified to USP 40 and Ph.Eur. 10.0 ^{[5]BASF, PronovaPure Omega-3 Product Portfolio Overview, January 2025, pharmaceutical.basf.com}.

Enzymatic processing is forecast to expand at approximately 9.2% CAGR, from USD 415.2 million in 2025 to USD 994.6 million by 2035. Its role is downstream and economically specific: hydrolysis, transesterification, and re-esterification help create rTG and free-fatty-acid forms that command different application and price positions. KD Pharma's kd-pür platform combines multi-step distillation with supercritical CO₂ chromatography and offers EE, rTG, and FFA formats with EPA/DHA content up to 99% ^{[6]KD Pharma, Marine-Based Omega-3 Concentrates, date not available, kdnutra.kdpharmagroup.com}. Supercritical fluid extraction, at USD 160.1 million in 2025, and membrane filtration, at USD 134.4 million, provide complementary routes where fractionation or finishing requirements justify their additional cost. Urea complexation and winterization remain relevant to mid-concentration and food-oriented supply, but their slower growth reflects less differentiation.

By output product form

EE remains the largest form, at USD 1,395.7 million in 2025, because it is an established distillation output and a familiar pharmaceutical intermediate. Its projected 6.4% CAGR nevertheless trails premium formats. Ultra-high or pharmaceutical-grade EE is forecast to grow approximately 8.2%, indicating that EE is not a uniformly commoditized category; specification and regulatory suitability still create a high-value tier.

rTG is forecast to rise from USD 537.7 million in 2025 to USD 1,193.5 million by 2035. Its advantage is commercial as well as technical: rTG makes an absorption-led proposition available to supplement brands while requiring processing expertise that standard EE does not. Epax states that its TGN line guarantees at least 90% rTG, versus an industry minimum cited at 50%. Phospholipids are forecast to be the fastest-growing output form at approximately 9.5% CAGR, supported by demand for differentiated marine-lipid delivery systems. The mix shift raises the importance of controlling oxidation, sensory performance, and stability through the entire conversion process.

By application

Dietary supplements and nutraceuticals are the largest application, with USD 1,144.6 million in 2025 and a projected 6.5% CAGR. Cardiovascular health is the largest supplement sub-application, whereas cognitive and brain-health use is projected to grow faster. The implication is a broader portfolio need: large-volume supplement demand supports scale, but it does not necessarily require the same form, purity, or documentation as clinical customers.

Pharmaceuticals and clinical nutrition grow faster, at approximately 7.8%, and their higher average selling prices reflect contractual quality and testing requirements. Food and beverage fortification, valued at USD 314.3 million in 2025, benefits from functional formats but faces formulation constraints around taste and stability. Infant and maternal nutrition reached USD 231.3 million, while animal feed and aquaculture reached USD 205.6 million. Aquaculture demand links concentrates to fish-feed formulation and desired fatty-acid profiles, creating an outlet with different price and specification logic from human nutrition. Pet food and veterinary nutrition adds another diversification channel, although its purchasing decisions are generally less regulation-led than infant formula.

By source species

Anchovy and anchoveta remain the largest source category at USD 964.7 million in 2025, reflecting high oil yield and Peru's processing scale. This leadership is also the source of the market's concentration risk. Sardine, pilchard, and mackerel support established European and Chinese supply chains, while herring remains important to the Norwegian and Icelandic cluster.

Salmonids and tuna are forecast to grow faster than the market average. Their significance lies in sourcing architecture: salmon trimmings from aquaculture and tuna by-products from canning can provide feedstock streams that are not governed by the same seasonal pelagic-fishery window. They do not eliminate anchoveta dependence, but they can broaden procurement options and support DHA-oriented formulation. Other species, including cod, menhaden, and pollock, further diversify supply and allow processors to match raw-material characteristics to specific formats or applications.

The source-species mix adds a less obvious competitive dimension. Salmon and tuna inputs are attractive not only because of growth rates, but because they may reduce exposure to a single seasonal pelagic supply system. A processor with access to varied raw materials and multiple conversion technologies can allocate feedstock toward the format with the best available economics. That flexibility is more valuable during supply shocks than a narrow product portfolio, even if the latter has high nominal concentration capacity.

Fish Oil Concentration and Refinement Market Regional Analysis

Europe

Europe is the largest regional market, generating approximately USD 791 million in 2025 and forecast to expand at approximately 6.6% CAGR. Norway is the region's processing center, with BASF, Epax, and GC Rieber VivoMega operating high-specification marine-lipid capacity. Germany and France each represented about USD 128.5 million in 2025, while Italy and Spain each represented about USD 102.8 million. EU formula DHA rules support regional demand for qualified ingredients. The United Kingdom's approximately 5.0% growth is below the regional rate, consistent with a mature market and regulatory separation from the EU framework. Europe's importance rests not only on consumption but on its ability to supply premium and pharmaceutical-grade concentrate globally.

North America

North America generated approximately USD 739.4 million in 2025. The United States accounted for USD 636.6 million, supported by a large supplement channel and pharmaceutical demand. U.S. fish-oil supplement sales volume increased 10% in 2024, according to SPINS data reported with Epax's investment announcement ^{[7]NutraIngredients, Epax Invests $10M in Omega-9 and Omega-11 Innovation, February 2025, nutraingredients.com}. Canada contributes both consumption and manufacturing relevance: KD Pharma's acquisition included the Mulgrave, Nova Scotia facility, connecting regional supply to its broader high-concentration platform. The region's large retail base supports scale, but qualification and brand positioning determine whether suppliers participate in commodity supplements or premium formats.

Asia Pacific

Asia Pacific is the fastest-growing region, generating approximately USD 706 million in 2025 and expanding at approximately 7.5% CAGR. China, at USD 262.9 million, combines supplement demand, infant-formula compliance, and domestic processing by KinOmega Biopharm and Sinomega. India, at USD 134.4 million, is forecast to grow about 8.3%, supported by expanding nutraceutical and pharmaceutical activity. Japan is a mature, high-specification market; GC Rieber VivoMega's distribution arrangement with Freemen Nutra reflects the importance of local commercialization partners for premium ingredients. South Korea's established rTG premium context reinforces format-led demand. Asia Pacific's growth is strong, but advanced qualification capacity has not yet fully converged with regional consumption, preserving import opportunities for European and North American processors.

Latin America

Latin America generated approximately USD 179.9 million in 2025. Brazil and Mexico are the principal consumption markets, at roughly USD 77.1 million and USD 51.4 million, respectively. The region's strategic importance exceeds those sales figures because Peru supplies a large share of global crude fish oil, while Chilean processor Golden Omega links South American anchovy resources to North American and European customers. This creates a split regional profile: raw-material risk and concentration capacity are located close together but finished-concentrate consumption is still more import- and brand-led in many Latin American markets.

Middle East and Africa

The Middle East and Africa generated approximately USD 154.2 million in 2025. Saudi Arabia and the UAE are the leading Gulf consumption markets, while South Africa serves as a distribution gateway to sub-Saharan demand. Regional growth is supported by supplement retail and fortified nutrition, but limited indigenous high-purity concentration capacity leaves the market dependent on imports. Suppliers must therefore manage longer logistics chains and local distributor capability alongside the usual requirements for shelf life and sensory stability.

Latin America illustrates the inverse relationship. Its upstream role gives the region disproportionate influence over global availability, but its downstream concentrate market is smaller than its feedstock significance. A disruption in Peru can affect European, North American, and Asian processors simultaneously. This makes geographically diversified sales less protective than diversified sourcing; the commercial advantage rests with firms that can connect regional market access to a resilient crude-oil procurement strategy.

Fish Oil Concentration and Refinement Market Share & Competitive Landscape

Competition is segmented by quality tier, process breadth, and access to feedstock rather than by one uniform market share. BASF SE supplies PronovaPure and Maxomega EPA/DHA concentrates with USP 40 and Ph.Eur. 10.0 specifications. KD Pharma Group SA strengthened its scale through the dsm-firmenich marine-lipids acquisition, which included MEG-3 and facilities in Piura and Mulgrave; dsm-firmenich retained a minority stake. Its multi-format technology positions it across pharmaceutical, clinical, and premium supplement demand.

Epax Norway AS competes in high-purity rTG and specialty lipids. Its Aalesund investment is intended to support omega-9 and omega-11 extraction, while its April 2025 EPAX Evolve 05 launch extended the portfolio into VLC-PUFA concentrates. GC Rieber VivoMega completed its expanded Kristiansund manufacturing campus in 2024 and subsequently introduced VivoTech and VivoSure quality technologies. These moves matter because premium customers procure reproducibility, shelf-life assurance, and regulatory support as part of the ingredient, not as optional services.

Golden Omega uses its Chilean location to connect anchovy supply with pharmaceutical- and supplement-grade exports. OLVEA Fish Oils, Polaris, and Lysi hf serve European and international food and supplement customers from established marine-oil positions. Croda International participates through specialty and delivery-oriented applications. KinOmega Biopharm and Sinomega serve China's developing domestic demand, while Wiley Companies/AlaskOmega emphasizes Alaska pollock origin and traceability. Aker BioMarine Antarctic AS broadened beyond krill with Revervia, a vegan algal DHA ingredient, and PL+ phospholipid innovation ^{[8]Aker BioMarine, Annual Report 2024, March 2025, akerbiomarine.com}. Nissui Pharmaceutical Co., Ltd. supplies EPA-E concentrates for Japan's prescription market. Together, these companies show that the competitive field includes marine, by-product, krill, and algal pathways; their substitutability varies materially by specification and end use.

Recent Industry Developments

October 2024 - KD Pharma completed the acquisition of dsm-firmenich's marine-lipids business. The transaction included the MEG-3 brand and manufacturing facilities in Piura, Peru, and Mulgrave, Canada, and created the largest omega-3 manufacturer by volume. It combined KD Pharma's high-concentration capabilities with an established larger-volume ingredient platform.

May 2024 - GC Rieber VivoMega opened its expanded Kristiansund campus. The USD 75 million project doubled output of high-purity triglyceride marine omega-3s and certified vegan algal oils; the site includes a 38,000-metric-ton storage tank park and renewable-energy infrastructure.

January 2025 - GC Rieber VivoMega announced VivoTech and VivoSure. The company stated that the technologies provide real-time quality monitoring and support a three-year shelf-life guarantee for finished oils.

February and April 2025 - Epax announced an Aalesund investment and launched EPAX Evolve 05. The USD 10 million project targets omega-9 and omega-11 extraction and was scheduled for early-2026 commissioning. Evolve 05 was launched as a VLC-PUFA concentrate; Epax reported EFSA confirmation that it was not a Novel Food.

2024 - Aker BioMarine launched Revervia and obtained a PL+ patent. Revervia is a vegan microalgae-derived DHA ingredient, and the company reported its first patent for PL+, a krill-phospholipid ingredient.